Brown Advisory Inc Lyell Immunopharma, Inc. Transaction History

Brown Advisory Inc

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 09, 2022	SELL	$5.05 - $7.7 $2.73 Million - $4.16 Million	-539,972 Closed	0 $0
Q4 2021 Jan 27, 2022	BUY	$7.13 - $15.19 $593,216 - $1.26 Million	83,200 Added 18.21%	539,972 $4.18 Million
Q3 2021 Nov 12, 2021	BUY	$11.0 - $17.95 $5.02 Million - $8.2 Million	456,772 New	456,772 $6.76 Million

122

142M

18.1K

200

Ticker LYEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 247,824,992
Market Cap $151M
Description
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...

Get notified when there are updates to the investment portfolio of Brown Advisory Inc, based on Form 13F filings with the SEC.

Stay updated on Brown Advisory Inc with notifications on news.